StocksMedium•9 November 2026•
1 min read
Ocular Therapeutix Q3 Revenue Misses Estimates with 11.5% Decline
Key Facts
1Ocular Therapeutix reported Q3 revenue of $12.87 million, missing analyst estimates of $13.92 million.
2The GAAP loss per share was $0.42, missing consensus estimates by 16.1%, with revenue declining 11.5% year-on-year.
Ocular Therapeutix reported Q3 2026 revenue of $12.87 million, missing analyst estimates of $13.92 million. FinancialContent reported that the GAAP loss per share reached $0.42, missing consensus estimates by 16.1%, while revenue declined by 11.5% on a year-on-year basis.
OCUL closed at $6.6 on November 6, 2026, prior to the release of results showing a decline in financial performance compared to the same period last year. According to FinancialContent, earnings per share dropped from a loss of $0.38 in the prior-year quarter to a loss of $0.42 in the current quarter, amid ongoing revenue growth challenges.